AlphaBio of Shanghai Announces $65 Million Series A Round

Alpha Biopharma of Shanghai has closed $37 million of a $65 million Series A financing led by Qiming Venture Partners. AlphaBio's lead product is a next-gen small molecule tyrosine kinase inhibitor aimed at EGFR mutation positive non-small cell lung cancer (NSCLC) patients with central nervous system metastases. AZD3759, discovered by AstraZeneca, is specifically designed to cross the blood-brain barrier, which most EFGR targeting molecules cannot do, says AlphaBio. The financing will support a global Phase II trial of AZD3759. More details.... Stock Symbol: (NYSE: AZN) Share this with colleagues: // //